INCY News and Press, Incyte Corporation From 02/15/24

2024-02-15 10:18:57 ET Summary MacroGenics, Inc. has a pipeline of promising drugs including Vobramitamab Duocarmazine, Lorigerlimab, Tebotelimab, MGD024, and IMGC936. The company has a strong financial position as of their latest report. MacroGenics faces both strengths and r...

2024-02-14 15:20:31 ET More on Incyte Incyte Corporation (INCY) Q4 2023 Earnings Call Transcript Incyte Corporation 2023 Q4 - Results - Earnings Call Presentation Incyte: Overly Reliant On Jakafi Despite Positive Phase 2 Results For Axatilimab Incyte Q4 2023 ...

2024-02-14 09:15:02 ET Truist Financial analyst issues MARKET OUTPERFORM recommendation for INCY on February 14, 2024 09:00AM ET. The previous analyst recommendation was Market Outperform. INCY was trading at $59.34 at issue of the analyst recommendation. The overall ana...

2024-02-14 09:15:02 ET Mizuho Securities analyst issues UNDERPERFORM recommendation for INCY on February 14, 2024 09:00AM ET. The previous analyst recommendation was Underperform. INCY was trading at $59.34 at issue of the analyst recommendation. The overall analyst cons...

2024-02-13 15:50:11 ET Summary AbCellera Biologics Inc. saw a significant decline in revenue due to the end of the COVID-19 pandemic, but has a large cash hoard and continues to expand partnerships. Analyst firms continue to Buy/Outperform ratings on the stock, but the company's p...

2024-02-13 12:37:03 ET Incyte Corporation (INCY) Q4 2023 Earnings Conference Call February 13, 2024, 08:00 AM ET Company Participants Ben Strain - Associate Vice President, Investor Relations Hervé Hoppenot - Chief Executive Officer Barry Flannelly - General...

2024-02-13 07:10:06 ET Incyte press release ( NASDAQ: INCY ): Q4 Non-GAAP EPS of $1.06 misses by $0.09 . Revenue of $1.01B (+9.0% Y/Y) beats by $10M . 2024 Financial Guidance ... Read the full article on Seeking Alpha For further details s...

Total FY'23 net product and royalty revenues of $3.7 billion (+14% Y/Y); total FY'23 net product revenues of $3.2 billion (+15% Y/Y) Jakafi ® (ruxolitinib) net revenues of $2.6 billion (+8%) for FY'23; Jakafi net revenues guidance range of $2,690 - $2,750 million for FY 2024 ...

ESSA Pharma Inc. (EPIX) is expected to report $-0.17 for Q1 2024 QuidelOrtho Corp Com (QDEL) is expected to report $2.01 for Q4 2023 FaZe Holdings Inc. (FAZE) is expected to report for Q4 2023 Portsmouth Square, Inc. (PRSI) is expected to report for Q2 2024 Similarweb Ltd. (SMWB) ...

2024-02-12 11:41:12 ET More on Incyte Incyte: Overly Reliant On Jakafi Despite Positive Phase 2 Results For Axatilimab Incyte buys global rights for tafasitamab from MorphoSys Agilent, Incyte to collaborate on companion diagnostics development Seeking Alpha&#...